TY - JOUR
T1 - Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
AU - Cheson, Bruce D.
AU - Greenberg, Peter L.
AU - Bennett, John M.
AU - Lowenberg, Bob
AU - Wijermans, Pierre W.
AU - Nimer, Stephen D.
AU - Pinto, Antonio
AU - Beran, Miloslav
AU - De Witte, Theo M.
AU - Stone, Richard M.
AU - Mittelman, Moshe
AU - Sanz, Guillermo F.
AU - Gore, Steven D.
AU - Schiffer, Charles A.
AU - Kantarjian, Hagop
PY - 2006/7/15
Y1 - 2006/7/15
N2 - The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment. Therapeutic trials in MDS have used various criteria to assess results, making cross-study comparisons problematic. In 2000, an International Working Group (IWG) proposed standardized response criteria for evaluating clinically significant responses in MDS. These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life. The relevance of the response criteria has now been validated prospectively in MDS clinical trials, and they have gained acceptance in research studies and in clinical practice. Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria.
AB - The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment. Therapeutic trials in MDS have used various criteria to assess results, making cross-study comparisons problematic. In 2000, an International Working Group (IWG) proposed standardized response criteria for evaluating clinically significant responses in MDS. These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life. The relevance of the response criteria has now been validated prospectively in MDS clinical trials, and they have gained acceptance in research studies and in clinical practice. Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria.
UR - http://www.scopus.com/inward/record.url?scp=33745968917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745968917&partnerID=8YFLogxK
U2 - 10.1182/blood-2005-10-4149
DO - 10.1182/blood-2005-10-4149
M3 - Review article
C2 - 16609072
AN - SCOPUS:33745968917
SN - 0006-4971
VL - 108
SP - 419
EP - 425
JO - Blood
JF - Blood
IS - 2
ER -